Literature DB >> 1861861

Effects of MGSA/GRO alpha on melanocyte transformation.

E Balentien1, B E Mufson, R L Shattuck, R Derynck, A Richmond.   

Abstract

In the work described here we demonstrate that the clonal cell line Mel-a-6, produced by transfection of mouse Melan-a cells with human MGSA, had an increased ability to form large colonies in soft agar and increased ability to form tumors when injected into nude mice as compared to cells transfected with the neomycin resistance gene alone. This effect appeared to be dependent on the levels of MGSA produced since another transfected clone, Mel-a-l, produced only a low level of MGSA transgene mRNA, formed only minimal large colonies in soft agar and had a tumorigenic rate equal to that of neomycin resistant controls. The histology of the Mel-a-6 tumors is compatible with features normally exhibited by melanoma tumors. The cells do not stain for melanin, and they are positive for the neural crest marker protein S-100 as well as the HMB 45 melanoma specific antigen. Immunohistochemical studies revealed expression of the human MGSA in tumor cells from tissues, excised from animals injected with cells from clone Mel-a-6. Whereas DNA ploidy analysis suggests that in vitro the Mel-a parent cell line, control Mel-a-neo, Mel-a-1 and Mel-a-6 cells show no evidence of aneuploidy, the nuclei isolated from the tumors from animals injected with Mel-a-6 do exhibit aneuploidy. These data suggest that over-expression of MGSA in immortalized melanocytes contributes to transformation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861861

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.

Authors:  Gong Yang; Daniel G Rosen; Guangzhi Liu; Fan Yang; Xiaoqing Guo; Xue Xiao; Fengxia Xue; Imelda Mercado-Uribe; Jiaoti Huang; Sue-Hwa Lin; Gordon B Mills; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

2.  Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1.

Authors:  K I Amiri; H C Ha; M E Smulson; A Richmond
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 3.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

4.  The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC.

Authors:  C W Smith; Z Chen; G Dong; E Loukinova; M Y Pegram; L Nicholas-Figueroa; C Van Waes
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 5.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

Review 6.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

Review 7.  Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.

Authors:  Yarí E Marín; Suzie Chen
Journal:  J Mol Med (Berl)       Date:  2004-08-21       Impact factor: 4.599

Review 8.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 9.  Senescent cells as a source of inflammatory factors for tumor progression.

Authors:  Albert R Davalos; Jean-Philippe Coppe; Judith Campisi; Pierre-Yves Desprez
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 10.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.